XBiotech (XBIT)
(Delayed Data from NSDQ)
$7.48 USD
+0.43 (6.10%)
Updated Oct 4, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for XBiotech Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 200 | 217 | 237 | 237 | 715 |
Receivables | 1 | 2 | 9 | 86 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 3 | 2 |
Total Current Assets | 202 | 220 | 247 | 326 | 716 |
Net Property & Equipment | 25 | 26 | 28 | 27 | 25 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 75 |
Deferred Charges | 0 | 0 | 0 | 1 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 227 | 246 | 275 | 354 | 817 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 2 | 1 | 1 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 49 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 5 |
Total Current Liabilities | 6 | 4 | 3 | 4 | 60 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 1 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 1 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 8 | 6 | 6 | 5 | 61 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 271 | 267 | 262 | 250 | 325 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -52 | -28 | 5 | 98 | 431 |
Other Equity | 0 | 1 | 2 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 219 | 240 | 269 | 349 | 756 |
Total Liabilities & Shareholder's Equity | 227 | 246 | 275 | 354 | 817 |
Total Common Equity | 219 | 240 | 269 | 349 | 756 |
Shares Outstanding | 30.40 | 30.40 | 30.40 | 29.20 | 41.50 |
Book Value Per Share | 7.20 | 7.91 | 8.86 | 11.94 | 18.21 |
Fiscal Year End for XBiotech Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 189 | 201 | 200 | 202 |
Receivables | NA | 1 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 1 | 1 |
Total Current Assets | NA | 191 | 203 | 202 | 204 |
Net Property & Equipment | NA | 25 | 25 | 25 | 25 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 216 | 228 | 227 | 230 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 3 | 3 | 1 |
Current Portion Long-Term Debt | NA | 10 | 10 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 5 | 4 | 4 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 17 | 17 | 6 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 2 | 2 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 19 | 19 | 8 | 7 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 272 | 272 | 271 | 270 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | -75 | -62 | -52 | -48 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 197 | 209 | 219 | 223 |
Total Liabilities & Shareholder's Equity | NA | 216 | 228 | 227 | 230 |
Total Common Equity | 0 | 197 | 209 | 219 | 223 |
Shares Outstanding | 30.40 | 30.40 | 30.40 | 30.40 | 30.40 |
Book Value Per Share | 0.00 | 6.47 | 6.88 | 7.20 | 7.32 |